Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
BeOne Medicines
Eli Lilly and Company
MOMA Therapeutics
Eli Lilly and Company
Eli Lilly and Company
Nammi Therapeutics Inc
National Cancer Institute (NCI)
Exscientia AI Limited
Conjupro Biotherapeutics, Inc.
Conjupro Biotherapeutics, Inc.
Zumutor Biologics Inc.
National Cancer Institute (NCI)
Orano Med LLC
Atavistik Bio, Inc
Alterome Therapeutics, Inc.
ViroMissile, Inc.
Tizona Therapeutics, Inc
Leiden University Medical Center
Clasp Therapeutics, Inc.
Angiex, Inc.
IDEAYA Biosciences
Oscotec Inc.
Innate Pharma
NeoTX Therapeutics Ltd.
Nuvation Bio Inc.
National Cancer Institute (NCI)
Exelixis
Senhwa Biosciences, Inc.
Jonsson Comprehensive Cancer Center
Novita Pharmaceuticals, Inc.
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
NextPoint Therapeutics, Inc.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Columbia University
Theratechnologies
Tomsk National Research Medical Center of the Russian Academy of Sciences
National Cancer Institute (NCI)
Carisma Therapeutics Inc
Eli Lilly and Company
Vincerx Pharma, Inc.
NGM Biopharmaceuticals, Inc
Optimal Health Research
Danatlas Pharmaceuticals Co., Ltd
Pfizer
Pfizer
NGM Biopharmaceuticals, Inc
Haihe Biopharma Co., Ltd.
OHSU Knight Cancer Institute